We found that TRX-01, as an oxazine-linked pyrimidine, could inhibit the proliferation of breast cancer MCF-7 cells, and in silico docking studies predicted that it can bind the p65 subunit of NF–κB (19). This evidence concerns the gene NFKB1 and breast carcinoma.